drugset / Trial / NCT07541430
A Study in Adults With Desmoid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This is an open-label, multicenter, single-arm phase 2 clinical study designed to evaluate the efficacy, safety, tolerability, patient-reported outcomes (PROs), pharmacokinetics (PK), anti-drug antibody (ADA) and pharmacodynamics (PD) of ES014 in adult desmoid tumor patients.
Timeline
- Start
- 2026-04-30
- Primary completion
- 2028-01
- Completion
- 2028-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ES014 | Protein / enzyme biologic | 700 mg | Intravenous |
| Subject | ES014 | Protein / enzyme biologic | 1400 mg | Intravenous |